BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: Wingless-type MMTV integration site family member 16 (WNT16)

Cancer INDICATION: Colon cancer In vitro studies suggest analogs of the natural product ellagic acid could help treat colon cancer. Chemical synthesis and in vitro testing of ellagic acid analogs identified a lead compound that...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...prevent bone loss and consequent bone fractures. Loss-of-function WNT16B mutations in patients and knockout of Wnt16b...
...low bone mineral density and/or increased risk of nonvertebral bone fractures. In mice, injection of WNT16B-loaded...
...loss compared with injection of empty liposomes. In rats receiving bisphosphonate-coated shinbone implants, injection of WNT16B-loaded...
BioCentury | Aug 30, 2012
Distillery Therapeutics

Indication: Cancer

...Publication and contact information Cancer Cancer Wingless-type MMTV integration site family member 16B (WNT16B) Human tissue and mouse studies suggest inhibiting stromal WNT16B...
...In tissue samples isolated from patients with breast, ovarian or prostate cancer treated with chemotherapy, WNT16B...
...plus normal fibroblasts but not prostate cancer cells plus WNT16B-expressing fibroblasts. Next steps include developing WNT16B...
Items per page:
1 - 3 of 3